DNTH - Company ID 0001690585
The table below shows Dianthus Therapeutics, Inc. /DE/'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $396.00K | $193.00K | $1.16M | $2.17M | $1.86M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $34.53M | $32.49M | $26.25M | $27.00M | $25.54M | $18.07M |
Dianthus Therapeutics, Inc. /DE/ reported annual revenue of $2.04M for fiscal year 2025. That is down 67.3% from $6.24M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $12.47M |
| $8.20M |
| $8.87M |
| $7.34M |
| $6.53M |
| $6.00M |
| Operating income | -$46.53M | -$40.29M | -$34.93M | -$33.18M | -$29.90M | -$22.20M |
| Income tax | - | - | - | - | - | - |
| Net income | -$40.83M | -$36.77M | -$31.63M | -$29.51M | -$25.17M | -$17.61M |
| EPS (diluted) | -$0.85 | -$0.97 | -$0.88 | -$0.82 | -$0.74 | -$0.51 |